Clinical Trial Update: A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial is evaluating intrathecally administered ION283 for Lafora disease and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lafora Disease

Drugs mentioned

• ION283

Snippet

Sponsor: Berge Minassian | Conditions: Lafora Disease | Phase 1, Phase 2 | Status: RECRUITING